Related Experiment Video
Updated: Jan 24, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
MicroRNA-664 functions as an oncogene in cutaneous squamous cell carcinomas (cSCC) via suppressing interferon
Xiangzhi Li1, Cheng Zhou2, Chen Zhang1
1Department of Radiation Medicine, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Background:
Aberrant expression of microRNA-664 was involved in tumor growth and metastasis of various cancers. The specific role of miR-664 in cutaneous squamous cell carcinoma (cSCC) is yet to be elucidated.
Objective:
The present study aimed to investigate the molecular mechanisms underpinning of cSCC development and provide translational insights for future therapeutics.
Methods:
Human cSCC specimens were used to determine the miR-664 by in situhybridization and IRF2 by immunohistochemistry. To study the potential mechanisms in tumorigenesis, three cSCC cell lines including HSC-5, HSC-1 and A431 as well as BALB/C mouse tumor model was utilized.
Results:
We found that miR-664 was remarkably high in cSCC patient specimens and cSCC cell lines. Overexpression of miR-664 promotes tumorigenic behaviors such as increased cell proliferation, migration and invasion capacities in vitro and enhanced tumorigenicity in xenograft mouse model. Our data further identified IRF2 as a direct downstream target of miR-664. Knockdown of IRF2 reverses pro-tumorigenesis phenotype of miR-664; whereas IRF2 over-expression inhibits miR-664 tumorigenesis in cSCC. Together, it revealed miR-664 functions as an oncogene in cSCC via suppression of IRF2.
Conclusion:
Our data demonstrates that aberrant expression of miR-664 plays a critical role in carcinogenesis of cSCC. The discovery of novel targets such as miR-664 and IRF2 will facilitate future development of therapeutic interventions.
Insights
MicroRNA-664 (miR-664) acts as an oncogene in cutaneous squamous cell carcinoma (cSCC) by promoting tumor growth and metastasis. Targeting miR-664 and its downstream target IRF2 may offer new therapeutic strategies for cSCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant microRNA-664 (miR-664) expression is implicated in various cancers.
- The specific role of miR-664 in cutaneous squamous cell carcinoma (cSCC) remains unclear.
Purpose of the Study:
- Investigate the molecular mechanisms of miR-664 in cSCC development.
- Identify potential therapeutic targets for cSCC.
Main Methods:
- Analyzed miR-664 and IRF2 expression in human cSCC specimens and cell lines.
- Utilized cSCC cell lines and a mouse tumor model to study tumorigenesis.
- Investigated the regulatory relationship between miR-664 and IRF2.
Main Results:
- miR-664 was significantly upregulated in cSCC tissues and cell lines.
- Overexpression of miR-664 enhanced cSCC cell proliferation, migration, invasion, and tumorigenicity in vivo.
- IRF2 was identified as a direct downstream target of miR-664; its suppression by miR-664 drives cSCC progression.
Conclusions:
- Aberrant miR-664 expression is a critical factor in cSCC carcinogenesis.
- miR-664 functions as an oncogene in cSCC by suppressing IRF2.
- miR-664 and IRF2 represent potential therapeutic targets for cSCC treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Transcription Factors
Cis-regulatory Sequences
Cis-regulatory Sequences
Global Regulatory Systems

